Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)
Close on Nov 17, 2026Market cap $6.07BP/E –Yield –
Arrowhead Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Arrowhead Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$59.06M, down 370.3% year over year. For fiscal 2025 it was $179.55M. The highest annual figure on record is $179.55M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $179.55M | – |
| FY2024 | Sep 30, 2024 | -$462.85M | – |
| FY2023 | Sep 30, 2023 | -$153.89M | – |
| FY2022 | Sep 30, 2022 | -$136.13M | -179.5% |
| FY2021 | Sep 30, 2021 | $171.31M | – |
| FY2020 | Sep 30, 2020 | -$95.80M | -155.4% |
| FY2019 | Sep 30, 2019 | $173.04M | – |
| FY2018 | Sep 30, 2018 | -$47.22M | – |
| FY2017 | Sep 30, 2017 | -$23.94M | – |
| FY2016 | Sep 30, 2016 | -$64.43M | – |
| FY2015 | Sep 30, 2015 | -$65.71M | – |
| FY2014 | Sep 30, 2014 | -$35.42M | – |
| FY2013 | Sep 30, 2013 | -$19.03M | – |
| FY2012 | Sep 30, 2012 | -$15.34M | – |
| FY2011 | Sep 30, 2011 | -$7.66M | – |
| FY2010 | Sep 30, 2010 | -$5.05M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$177.47M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $84.44M | -81.6% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $13.48M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $20.49M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$154.72M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $460.05M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$146.27M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$137.22M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$115.42M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$92.38M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$117.84M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$25.93M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$20.78M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$31.67M | -150.5% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$75.52M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$68.74M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$68.82M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $62.73M | -76.2% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$61.31M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$24.03M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$29.61M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $263.87M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$38.92M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$11.26M | -181.5% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$33.43M | -417.5% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$27.59M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$23.53M | -114.0% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $13.81M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $10.53M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$19.59M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $168.28M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$2.68M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$14.41M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$15.44M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$14.69M | -246.9% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$9.20M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$10.41M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$14.33M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $10.00M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$10.18M | – |
See a number that looks wrong?